Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.
The branch of science concerned with the means and consequences of transmission and generation of the components of biological inheritance. (Stedman, 26th ed)
Substances that are recognized by the immune system and induce an immune reaction.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antibodies produced by a single clone of cells.

Alternative pathways of T lymphocyte activation. (1/1635)

Data presented in this paper suggest that there may be two alternative pathways which T lymphocytes can use in generating a cytotoxic response to alloantigens in vitro. First, there is the pathway taken when stimulator and responder cells differ by an entire H-2 complex where Ly1+2- helper T lymphocytes respond to I region encoded lymphocyte defined differences and provide help to the Ly1-2+ cytotoxic T lymphocytes responsive primarily to K/D region encoded cytotoxicity defined determinants. Second, there is the pathway taken when stimulator and responder cells differ by only K or D region differences without an I region encoded difference; under these conditions, an Ly1+2+ cell, which does not appear to play a significant role in the development of a cytotoxic response to an entire H-2 difference, appears to play a pivotal role.  (+info)

Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. (2/1635)

A number of antibodies generated during human respiratory syncytial virus (RSV) infection have been cloned by the phage library approach. Antibodies reactive with an immunodominant epitope on the F glycoprotein of this virus have a high affinity for affinity-purified F antigen. These antibodies, however, have a much lower affinity for mature F glycoprotein on the surface of infected cells and are nonneutralizing. In contrast, a potent neutralizing antibody has a high affinity for mature F protein but a much lower affinity for purified F protein or F protein in viral lysates. The data indicate that at least two F protein immunogens are produced during natural RSV infection: immature F, found in viral lysates, and mature F, found on infected cells or virions. Binding studies with polyclonal human immunoglobulin G suggest that the antibody responses to the two immunogens are of similar magnitudes. Competitive binding studies suggest that overlap between the responses is relatively limited. A mature envelope with an antigenic configuration different from that of the immature envelope has an evolutionary advantage in that the infecting virus is less subject to neutralization by the humoral response to the immature envelope that inevitably arises following lysis of infected cells. Subunit vaccines may be at a disadvantage because they most often resemble immature envelope molecules and ignore this aspect of viral evasion.  (+info)

Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. (3/1635)

The interaction of the T-cell receptor with the major histocomatibility complex (MHC)-peptide complex is central to T-cell activation. Variation in the nature of the peptide bound within the groove of the MHC molecule may result in an altered T-cell response. Because some naturally processed peptides bound within the groove of the class II MHC molecule are derived from the MHC molecules themselves, we studied the inhibitory effects of synthetic class II MHC peptides on alloimmune responses in vitro. Three peptides derived from a highly conserved region of the class II MHC alpha chains inhibited the rat mixed lymphocyte response (MLR) in a dose-dependent manner, with the human HLA-DQA1 peptide also inhibiting the human and mouse MLR. No effect was seen on mitogen-induced T-cell proliferation. HLA-DQA1 inhibited cytolytic T lymphocyte (CTL) generation in a dose-response fashion, with no reduction in preformed CTL killing, suggesting that the inhibitory effect is targeted at CD4(+) T-cell function. Cell-cycle analysis by flow cytometry showed that restimulation of primed T cells in the presence of HLA-DQA1 resulted in increased apoptosis, whereas unstimulated cells were not affected. These data demonstrate that synthetic peptides derived from highly conserved regions of the class II MHC alpha chain can alter CD4(+) T-lymphocyte alloimmune responses in vitro, and this effect is mediated by the induction of apoptosis in activated T cells.  (+info)

Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. (4/1635)

Two unrelated patients with the same Arg2150His mutation in the factor VIII (FVIII) C1 domain, a residual FVIII activity of 0.09 IU/mL, and inhibitor titres of 300 and 6 Bethesda Units, respectively, were studied. Further analysis of patient LE, with the highest inhibitor titer, showed that (1) plasma or polyclonal IgG antibodies prepared from LE plasma inhibited the activity of allogeneic (wild-type) but not of self FVIII; (2) the presence of von Willebrand factor (vWF) increased by over 10-fold the inhibitory activity on wild-type FVIII; (3) the kinetics of FVIII inhibition followed a type II pattern, but in contrast to previously described type II inhibitors, LE IgG was potentiated by the presence of vWF instead of being in competition with it; (4) polyclonal LE IgG recognized the FVIII light chain in enzyme-linked immunosorbent assay and the recombinant A3-C1 domains in an immunoprecipitation assay, indicating that at least part of LE antibodies reacted with the FVIII domain encompassing the mutation site; and (5) LE IgG inhibited FVIII activity by decreasing the rate of FVIIIa release from vWF, but LE IgG recognized an epitope distinct from ESH8, a murine monoclonal antibody exhibiting the same property. We conclude that the present inhibitors are unique in that they clearly distinguish wild-type from self, mutated FVIII. The inhibition of wild-type FVIII by LE antibody is enhanced by vWF and is associated with an antibody-dependent reduced rate of FVIIIa release from vWF.  (+info)

Isolation and characterization of monoclonal antibodies directed against murine FRP-1/CD98/4F2 heavy chain: murine FRP-1 is an alloantigen and amino acid change at 129 (P<-->R) is related to the alloantigenicity. (5/1635)

Nineteen mAb directed against murine fusion regulatory protein-1 (mFRP-1)/4F2/CD98 were isolated and their biological properties were analysed. Intriguingly, mFRP-1 was found to be an alloantigen, namely, FRP-1.1 (DBA/2 and CBA mice type) and FRP-1.2 (BALB/c, C57BL/6 and C3H/He mice type). The nucleotide sequences of FRP-1.1 and FRP-1.2 were determined, demonstrating that amino acid change at 129 (P<-->R) is related to the alloantigenicity. mFRP-1 is expressed on thymocytes, on spleen cells, on peripheral lymphocytes and on blood monocytes, suggesting that the physiological role in vivo of murine FRP-1 is different from that of human FRP-1. The biological activities of antimFRP-1 mAbs showed by the present study are: (i) enhancement of Newcastle disease virus-induced cell fusion; (ii) suppression of HIVgp160-mediated cell fusion; and (iii) induction of aggregation and multinucleated giant cells of monocytes/macrophages.  (+info)

Administration of G-CSF to normal individuals diminishes L-selectin+ T cells in the peripheral blood that respond better to alloantigen stimulation than L-selectin- T cells. (6/1635)

To determine whether administration of G-CSF induces phenotypic or functional changes in T cells, we examined peripheral blood T cells from normal individuals receiving G-CSF for activation antigen and adhesion molecule expression before and after G-CSF administration. G-CSF (10 microg/kg/day) was administered subcutaneously to 14 normal individuals for 3-5 days and their PBMC were serially analyzed with monoclonal Ab (mAb) directed to HLA-DR, CD45RO, CD45RA, CD25, CD122, CD95, CD11a, CD49d, CD44 and CD62L (L-selectin) coupled with anti-CD3 mAb. Among T cells positive for these antigens, only the proportion of T cells expressing L-selectin significantly decreased from 68% to 37% after 3-day G-CSF administration. When peripheral blood CD3+ T cells obtained before and after G-CSF administration were sorted into two populations depending on the expression of L-selectin and tested for their proliferative response to allogeneic B cells, the reactivity of L-selectin- cells to alloantigen stimulation was consistently lower than that of L-selectin+ cells regardless of the exposure to G-CSF. The decrease in the relative number of L-selectin+ cells induced by G-CSF administration may contribute to the unexpectedly low incidence of severe acute GVHD after allogeneic PBSC transplantation.  (+info)

Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. (7/1635)

Brief treatment with alphaCD154 Ab has been shown to prevent acute graft versus host disease (aGvHD). We extend these data to show that in the absence of CD154 function, donor T cells are unable to expand or generate high level anti-host CTL activity. Using transgenic (Tg) alloreactive CD8+ T cells adoptively transferred into allogeneic recipients, we show that short-term expansion of the CD8+ Tg T cells occurred in the absence of Th cells, and this short-term expansion could be facilitated with an agonistic alphaCD40. While CD40 agonism could enhance short-term expansion, sustained expansion of CD8+ Tg T cells required bona fide CD154-expressing CD4+ alloreactive Th cells. While CD154 was necessary for CD8+ Tg T cell sustained expansion, IL-2 was also implicated as essential. These observations suggest alphaCD154 therapy in GvHD is effective because the treatment causes an abortive CD8 alloresponse leading to the exhaustion or deletion of alloreactive CD8+ clones preventing the development of disease.  (+info)

T cell immunity induced by allogeneic microglia in relation to neuronal retina transplantation. (8/1635)

Microglia share a lineage relationship with bone marrow-derived monocytes/macrophages and dendritic cells, and their inclusion in retinal and brain transplants may function as "passenger leukocytes. " In other solid allografts, passenger leukocytes are the primary sources of immunogenicity, triggering alloimmune rejection. We have conducted a series of in vitro and in vivo studies examining the capacity of microglia cultured from forebrain to activate alloreactive T cells and to induce and elicit alloimmunity. Cultured microglia expressed class II MHC molecules and costimulatory molecules (B7-1, B7-2, and CD40), and they secreted IL-12. Cultured microglia injected s.c. into naive recipients induced allospecific delayed hypersensitivity and elicited delayed hypersensitivity directed at alloantigens. Cultured microglia differed from conventional APCs by secreting significant amounts of mature TGF-beta2, but smaller amounts of IL-12. Moreover, while both cultured microglia and conventional APC stimulated T cell proliferation in vitro, microglia directed the responding T cells toward the Th2 pathway in which IL-4, but not IL-2 and IFN-gamma, was secreted. The abilities of microglia to secrete TGF-beta2, to stimulate alloreactive Th2 cells, and to induce anterior chamber associated immune deviation when injected into the eye of naive allogeneic mice suggest that they are not typical passenger leukocytes. The unique functional properties of cultured microglia may account for the capacity of neonatal retinal tissue transplanted into the eye to alter the systemic alloimmune response in a manner that delays, but does not prevent, graft rejection.  (+info)

Isoantigens are antigens that are present on the cells or tissues of one individual of a species, but are absent or different in another individual of the same species. They are also known as "alloantigens." Isoantigens are most commonly found on the surface of red blood cells and other tissues, and they can stimulate an immune response when transplanted into a different individual. This is because the recipient's immune system recognizes the isoantigens as foreign and mounts a defense against them. Isoantigens are important in the field of transplantation medicine, as they must be carefully matched between donor and recipient to reduce the risk of rejection.

The ABO blood-group system is a classification system used in blood transfusion medicine to determine the compatibility of donated blood with a recipient's blood. It is based on the presence or absence of two antigens, A and B, on the surface of red blood cells (RBCs), as well as the corresponding antibodies present in the plasma.

There are four main blood types in the ABO system:

1. Type A: These individuals have A antigens on their RBCs and anti-B antibodies in their plasma.
2. Type B: They have B antigens on their RBCs and anti-A antibodies in their plasma.
3. Type AB: They have both A and B antigens on their RBCs but no natural antibodies against either A or B antigens.
4. Type O: They do not have any A or B antigens on their RBCs, but they have both anti-A and anti-B antibodies in their plasma.

Transfusing blood from a donor with incompatible ABO antigens can lead to an immune response, causing the destruction of donated RBCs and potentially life-threatening complications such as acute hemolytic transfusion reaction. Therefore, it is crucial to match the ABO blood type between donors and recipients before performing a blood transfusion.

Blood group antigens are molecular markers found on the surface of red blood cells (RBCs) and sometimes other types of cells in the body. These antigens are proteins, carbohydrates, or glycoproteins that can stimulate an immune response when foreign antigens are introduced into the body.

There are several different blood group systems, but the most well-known is the ABO system, which includes A, B, AB, and O blood groups. The antigens in this system are called ABO antigens. Individuals with type A blood have A antigens on their RBCs, those with type B blood have B antigens, those with type AB blood have both A and B antigens, and those with type O blood have neither A nor B antigens.

Another important blood group system is the Rh system, which includes the D antigen. Individuals who have this antigen are considered Rh-positive, while those who do not have it are considered Rh-negative.

Blood group antigens can cause complications during blood transfusions and pregnancy if there is a mismatch between the donor's or fetus's antigens and the recipient's antibodies. For example, if a person with type A blood receives type B blood, their anti-B antibodies will attack the foreign B antigens on the donated RBCs, causing a potentially life-threatening transfusion reaction. Similarly, if an Rh-negative woman becomes pregnant with an Rh-positive fetus, her immune system may produce anti-D antibodies that can cross the placenta and attack the fetal RBCs, leading to hemolytic disease of the newborn.

It is important for medical professionals to determine a patient's blood group before performing a transfusion or pregnancy-related procedures to avoid these complications.

Genetics is the scientific study of genes, heredity, and variation in living organisms. It involves the analysis of how traits are passed from parents to offspring, the function of genes, and the way genetic information is transmitted and expressed within an organism's biological system. Genetics encompasses various subfields, including molecular genetics, population genetics, quantitative genetics, and genomics, which investigate gene structure, function, distribution, and evolution in different organisms. The knowledge gained from genetics research has significant implications for understanding human health and disease, as well as for developing medical treatments and interventions based on genetic information.

An antigen is a substance (usually a protein) that is recognized as foreign by the immune system and stimulates an immune response, leading to the production of antibodies or activation of T-cells. Antigens can be derived from various sources, including bacteria, viruses, fungi, parasites, and tumor cells. They can also come from non-living substances such as pollen, dust mites, or chemicals.

Antigens contain epitopes, which are specific regions on the antigen molecule that are recognized by the immune system. The immune system's response to an antigen depends on several factors, including the type of antigen, its size, and its location in the body.

In general, antigens can be classified into two main categories:

1. T-dependent antigens: These require the help of T-cells to stimulate an immune response. They are typically larger, more complex molecules that contain multiple epitopes capable of binding to both MHC class II molecules on antigen-presenting cells and T-cell receptors on CD4+ T-cells.
2. T-independent antigens: These do not require the help of T-cells to stimulate an immune response. They are usually smaller, simpler molecules that contain repetitive epitopes capable of cross-linking B-cell receptors and activating them directly.

Understanding antigens and their properties is crucial for developing vaccines, diagnostic tests, and immunotherapies.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Reif A., Allen J. (1966). "Mouse Thymic Iso-antigens". Nature. 209 (5022): 521-523. doi:10.1038/209521b0. PMID 5919593. S2CID ...
In 1977 the University of Aberdeen published her work, The ABH Isoantigens in Cervical Malignancy. In 1978 she was meant to ... ISBN 978-978-8012-36-8. Uyanwah, Philomena Obiagliuwa (1977). The ABH Isoantigens in Cervical Malignancy. Aberdeen University. ...
Flocks RH, Boatman DL, Hawtrey CE (November 1972). "Tissue specific isoantigens in the dog prostate". Investigative Urology. 10 ...
"Carcinoembryonic antigen: evidence for multiple antigenic determinants and isoantigens". Proceedings of the National Academy of ...
Ly-A and Ly-B: Two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci. 1968 Jun 11; 170(19): 175-193. ...
... , formerly called alloantibodies, are antibodies produced by an individual against isoantigens produced by members ...
... which are called alloantigens or isoantigens. Two major types of alloantigens are blood group antigens and histocompatibility ...
"Isoantigens" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Isoantigens" by people in this website by year, and whether " ... Below are the most recent publications written about "Isoantigens" by people in Profiles. ...
Reif A., Allen J. (1966). "Mouse Thymic Iso-antigens". Nature. 209 (5022): 521-523. doi:10.1038/209521b0. PMID 5919593. S2CID ...
Categories: Isoantigens Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted 3 ...
Prognostic significance of flow-DNA analysis and cell surface isoantigens in carcinoma of bilharzial bladder. Urology. 1992 Mar ...
Archive institutionnelle de lUniversité de Genève - Institutional Repository of the University of Geneva
Isoantigens (MeSH) * Male (MeSH) * Mice (MeSH) * Mice, Inbred Strains (MeSH) * Pregnancy (MeSH) ...
Mann, D.L., Rogentine, G.N. Jr., Fahey, J.L., & Nathenson, S.G. Solubilization of human leukocyte membrane isoantigens. Nature ...
... blood group isoantigens A, B, and H (BGI), epithelial antigens, vimentin, and actin; and Ulex europaeus I lectin (UEL) were ...
Similarly, since spermatozoa are not self and isoantigens to females, if they are exposed repeatedly to sperm antigens by ...
Isoantigens Medicine & Life Sciences 23% * Nerve Regeneration Medicine & Life Sciences 22% * Peripheral Nerves Medicine & Life ...
Blood group antigens and disease / presented by the Committee on Annual Meeting Seminar ; editor, George Garratty. - Arlington, Va. : American Association of Blood Banks, 1983. - 192 p ...
Isoantigens. Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by ... Immunosuppressive AgentsIsoantigensCyclosporineIsoantibodiesCyclosporinsTacrolimusAntilymphocyte SerumH-Y AntigenHLA Antigens ... Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.. ... VascularTransplantation ToleranceIsoantigensCyclosporineLiver TransplantationRats, Inbred LewImmunosuppressionIsoantibodiesMice ...
Dawson, G. J., Schlauder, G. G., Pilot-Matias, T. J., Thiele, D. L., Leary, T. P., Murphy, P., Rosenblatt, J. E., Simons, J. N., Martinson, F. E. A., Gutierrez, R. A., Lentino, J. R., Pachucki, C., Muerhoff, A. S., Widell, A., Tegtmeier, G., Desai, S. & Mushahwar, I. K., Sep 1996, In: Journal of Medical Virology. 50, 1, p. 97-103 7 p.. Research output: Contribution to journal › Article › peer-review ...
Yamashita, T., Ono, K., Ohuchi, H., Yumoto, A., Gotoh, H., Tomonari, S., Sakai, K., Fujita, H., Imamoto, Y., Noji, S., Nakamura, K. & Shichida, Y., Feb 14 2014, In: Journal of Biological Chemistry. 289, 7, p. 3991-4000 10 p.. Research output: Contribution to journal › Article › peer-review ...
isoantigens - immunology. 5. natural killer (nk) cell. 5. orthomyxoviridae infections - drug therapy - immunology - pathology. ...
Duivenvoorden, R., Tang, J., Cormode, D. P., Mieszawska, A. J., Izquierdo-Garcia, D., Ozcan, C., Otten, M. J., Zaidi, N., Lobatto, M. E., Van Rijs, S. M., Priem, B., Kuan, E. L., Martel, C., Hewing, B., Sager, H., Nahrendorf, M., Randolph, G. J., Stroes, E. S. G., Fuster, V., Fisher, E. A., & 2 othersFayad, Z. A. & Mulder, W. J. M., 2014, In: Nature communications. 5, 3065.. Research output: Contribution to journal › Article › peer-review ...
A. W. Thomson, J. M. Sacks, Y. R. Kuo, R. Ikeguchi, E. K. Horibe, J. Unadkat, M. G. Solari, M. Feili-Hariri, W. P.A. Lee ...
Isoantigens [D23.050.705]. *Histocompatibility Antigens [D23.050.705.552]. *Histocompatibility Antigens Class II [D23.050. ...
Isoantigens [D23.050.705]. *Blood Group Antigens [D23.050.705.230]. *Duffy Blood-Group System [D23.050.705.230.301] ...
Isoantigens [D23.050.705]. *Histocompatibility Antigens [D23.050.705.552]. *Histocompatibility Antigens Class II [D23.050. ...
Isoantigens Medicine & Life Sciences 100% * Lymphocytes Medicine & Life Sciences 42% * Blood Cells Medicine & Life Sciences 41% ...
We use cookies to ensure that we give you the best experience on our website. If you click Accept all cookies well assume that you are happy to receive all cookies and you wont see this message again. If you click Reject all non-essential cookies only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click Find out more for information on how to change your cookie settings. ...
Antibody Formation, Antigens, Cell Line, Hemocyanins, Hybrid Cells, Immunologic Memory, Immunosuppression, Isoantigens, T- ...
Prognostic significance of flow-DNA analysis and cell surface isoantigens in carcinoma of bilharzial bladder. Urology. 1992 Mar ...
Prognostic significance of flow-DNA analysis and cell surface isoantigens in carcinoma of bilharzial bladder. Urology. 1992 Mar ...
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. ...
Animals, Antilymphocyte Serum, Cell Differentiation, Cell Membrane, Epitopes, Immunoglobulin M, Immunosuppression, Isoantigens ...
To chomp any nonsyndicated contrivances, whomever isoantigens disjoint a chorioptic near to cheap fosamax in usa ectrosis ...
Antigens, Cell Line, Cytotoxicity Tests, Immunologic, Epitopes, Glycoproteins, Humans, Immune Sera, Isoantigens, Molecular ...
... which are called alloantigens or isoantigens. Two major types of alloantigens are blood group antigens and histocompatibility ...
  • Similarly, since spermatozoa are not self and isoantigens to females, if they are exposed repeatedly to sperm antigens by coitus, it is not surprising that isoimmunity to sperm antigens could be induced and develop antisperm antibodies (ASA) in females. (benthamscience.com)
  • and (3) almost every other polymorphic phone surface antigens (entitled alloantigens or isoantigens) that would be distinguished which have specifically set up "allo-antisera" (Boyse ainsi que al. (kenyan.bible)
  • Isoantigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (wakehealth.edu)